US3737549A - Method of treating depression - Google Patents

Method of treating depression Download PDF

Info

Publication number
US3737549A
US3737549A US00236180A US3737549DA US3737549A US 3737549 A US3737549 A US 3737549A US 00236180 A US00236180 A US 00236180A US 3737549D A US3737549D A US 3737549DA US 3737549 A US3737549 A US 3737549A
Authority
US
United States
Prior art keywords
patients
trh
treating depression
depressant
observed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00236180A
Other languages
English (en)
Inventor
N Plotnikoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of US3737549A publication Critical patent/US3737549A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • the present invention relates to an improved method of treating depression.
  • anti-depressant agents which are currently used in the treatment of patients sufliering from moderate to severe depression.
  • agents include imipramine, desipramine, amitriptyline, nortriptyline, protriptyline, doXepin, prothiadin, Triavil (perphenazine and amitriptyline hydrochloride), Etrafon (perphenazine and amitriptyline hydrochloride), chlorimipramine, noxiptilin and the like. While the above agents have been found to be effective in treating the symptoms of moderate to severe depression, there are several drawbacks to their use.
  • the present invention provides such a method.
  • TRH thyrotropin releasing hormone
  • TRH The anti-depressant activity of TRH was first established in mice using the modified dopa test [Everett, Fed. Proc. 23, p. 198 (1964)].
  • the responses in the modified dopa test are graded 1+ for slight increase in activity, 2+ for moderate activity and 3+ for market effects.
  • TRH exhibited marked activity at dosages of 0.4 and 0.8 mg./kg. both by the oral and the intraperitoneal routes. Moderate activity was observed at 0.2 mg./kg. i.p. and slight activity at 0.2 mg./kg. p.o. and 0.1 mg./kg. p.o. and i.p.
  • TRH a particularly useful anti-depressant agent for the reasons described hereinabove.
  • the compound useful in the practice of this invention can be formulated into various pharmaceutical dosage forms such as tablets, capsules, pills, sterile aqueous or non-aqueous solutions for parenteral administration, and the like, for immediate or sustained release, by combining one or more of the active compounds with suitable pharmaceutically acceptable carrier or diluents according to methods well known in the art.
  • Such dosage forms may additionally include excipients, binders, fillers, flavoring and sweetening agents and other therapeutically inert ingredients necessary in the formulation of the desired pharmaceutical preparation.
  • EXAMPLE 1 Tablets containing 400 mcg. of TRH and having the following composition are prepared according to methods well known in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US00236180A 1972-03-20 1972-03-20 Method of treating depression Expired - Lifetime US3737549A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23618072A 1972-03-20 1972-03-20

Publications (1)

Publication Number Publication Date
US3737549A true US3737549A (en) 1973-06-05

Family

ID=22888457

Family Applications (1)

Application Number Title Priority Date Filing Date
US00236180A Expired - Lifetime US3737549A (en) 1972-03-20 1972-03-20 Method of treating depression

Country Status (8)

Country Link
US (1) US3737549A (fr)
AU (1) AU474598B2 (fr)
BE (1) BE797004A (fr)
DE (1) DE2313635A1 (fr)
FR (1) FR2184595B1 (fr)
GB (1) GB1372664A (fr)
PH (1) PH9926A (fr)
ZA (1) ZA731379B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873709A (en) * 1974-02-19 1975-03-25 Abbott Lab Method of treating psychosis
DE2611976A1 (de) * 1975-04-03 1976-10-14 Takeda Chemical Industries Ltd Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5830866A (en) * 1994-09-12 1998-11-03 The Trustees Of The University Of Pennsylvania Corticotropin release inhibiting factor and methods of using same
US6039956A (en) * 1994-09-12 2000-03-21 Pennsylvania, Trustees Of The University Of, The Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder
US6475989B1 (en) * 1997-10-09 2002-11-05 Albert Sattin Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
US20030175350A1 (en) * 2000-07-11 2003-09-18 Katsuji Sugita Enteric preparations containing physiologically active peptides
US20050009753A1 (en) * 1997-10-09 2005-01-13 Albert Sattin Tri-peptides for neurological and neurobehavioral applications
US20050233973A1 (en) * 1997-10-09 2005-10-20 Albert Sattin Tri-peptides for antidepressant applications

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2227658A (en) * 1989-02-03 1990-08-08 Cellana Thyrotropin releasing hormone (trh) composition for enhancing immune function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737422A (en) * 1970-02-04 1973-06-05 Abbott Lab L-histidyl-l-proline amide

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873709A (en) * 1974-02-19 1975-03-25 Abbott Lab Method of treating psychosis
DE2611976A1 (de) * 1975-04-03 1976-10-14 Takeda Chemical Industries Ltd Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
FR2313075A1 (fr) * 1975-04-03 1976-12-31 Takeda Chemical Industries Ltd Medicament a base de l-pyroglutamyl-l-histidyl-l-prolinamide ou ses sels
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5830866A (en) * 1994-09-12 1998-11-03 The Trustees Of The University Of Pennsylvania Corticotropin release inhibiting factor and methods of using same
US6039956A (en) * 1994-09-12 2000-03-21 Pennsylvania, Trustees Of The University Of, The Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder
US6475989B1 (en) * 1997-10-09 2002-11-05 Albert Sattin Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
US20050009753A1 (en) * 1997-10-09 2005-01-13 Albert Sattin Tri-peptides for neurological and neurobehavioral applications
US20050233973A1 (en) * 1997-10-09 2005-10-20 Albert Sattin Tri-peptides for antidepressant applications
US20030175350A1 (en) * 2000-07-11 2003-09-18 Katsuji Sugita Enteric preparations containing physiologically active peptides

Also Published As

Publication number Publication date
DE2313635A1 (de) 1973-10-04
PH9926A (en) 1976-06-14
BE797004A (fr) 1973-09-19
FR2184595B1 (fr) 1976-07-02
GB1372664A (en) 1974-11-06
ZA731379B (en) 1973-11-28
AU5279973A (en) 1974-09-05
FR2184595A1 (fr) 1973-12-28
AU474598B2 (en) 1976-07-29

Similar Documents

Publication Publication Date Title
KR0164435B1 (ko) 비만증 치료용 약제학적 조성물
CA1198057A (fr) Methode de contraception par administration de progestogene
Wålinder et al. Potentiation of the antidepressant action of clomipramine by tryptophan
CA2317044C (fr) Medicament pour maladies neurodegeneratives
US3737549A (en) Method of treating depression
US5492907A (en) Antipsychotic composition and method of treatment
FI101040B (fi) Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi
HU226677B1 (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
EP1443933B1 (fr) Traitement de la leucemie myeloide chronique, resistante ou intolerante au sti571, impliquant l'homoharringtonine seul ou en combinaison avec d'autres agents
WO1993001812A1 (fr) S-(3-(4(5)-imidazolyl)propyl)isothiouree utilisee comme antagoniste selectif de recepteur de tristomine h3
WO2003041699A1 (fr) Preparations medicamenteuses actives de thyroxine a stockage stable et techniques de production de ces preparations
CA1261272A (fr) Combinaison de produit a dihydropyridine
US3699229A (en) 2-oxo-5-phenyl-4-oxazolidinone as an anti-depressant agent
PL190349B1 (pl) Kompozycja farmaceutyczna zawierająca lamiwudynę i zydowudynę, sposób jej wytwarzania, sposób zwiększania i utrzymywania jednorodności kompozycji farmaceutycznej, zastosowanie lamiwudyny oraz wyrób fabryczny
US3729563A (en) Method of treating movement disorders
JP4122544B2 (ja) 錠剤組成物
US3708593A (en) Use of l-prolyl l-leucyl glycine amide as an anti-depressant
JPH07126165A (ja) 腫瘍治療剤
US3110650A (en) Synergistic analgesic compositions
US3261752A (en) Method for reducing serum cholesterol
US3538224A (en) Composition for treating human mental disorders
NO134185B (fr)
US3478151A (en) Compositions of perphenazine and protriptyline for treating mental disorders
US3513235A (en) Method of controlling ascites tumors with chlorpheniramine maleate
US4879298A (en) Novel method and composition